SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla unveils generic hepatitis C drug 'Hepcvir-L'

21 Dec 2015 Evaluate

Cipla has unveiled generic tablets used for treating of hepatitis C under the brand name 'Hepcvir-L' costing Rs 25,000 for a bottle of 28 tablets in India. Hepcvir-L is the first once-a-day, fixed dose oral combination therapy that has been approved for chronic hepatitis C genotype 1 patient. The company's product is a generic version of the S-based drug maker Gilead Sciences Inc's Harvoni tablets.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Its portfolio includes 1500 plus products across therapeutic categories with one quality standard globally.

Cipla Share Price

1237.60 -0.70 (-0.06%)
20-Apr-2026 10:28 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.25
Dr. Reddys Lab 1235.65
Cipla 1237.60
Zydus Lifesciences 940.00
Lupin 2327.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×